A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Takanori Mizoguchi,1 Mineo Ozaki,2 Kazuhiko Unoki,3 Yoshinori Dake,4 Takahiko Eto,5 Miki Arai61Mizoguchi Eye Clinic, 2Ozaki Eye Clinic, Miyazaki, Japan; 3Unoki Eye Clinic, Kagoshima, Japan; 4Dake Eye Clinic, Nagasaki, Japan; 5Eto Eye Clinic, Oita, Japan; 6Arai Eye Clinic, Fukuoka, JapanPurpose: We c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/7a83617bd98544128a10758012128c47
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a83617bd98544128a10758012128c47
record_format	dspace
spelling	oai:doaj.org-article:7a83617bd98544128a10758012128c472021-12-02T00:51:43ZA randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma1177-54671177-5483https://doaj.org/article/7a83617bd98544128a10758012128c472012-09-01T00:00:00Zhttp://www.dovepress.com/a-randomized-crossover-study-comparing-tafluprost-0005-with-travoprost-a11098https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Takanori Mizoguchi,1 Mineo Ozaki,2 Kazuhiko Unoki,3 Yoshinori Dake,4 Takahiko Eto,5 Miki Arai61Mizoguchi Eye Clinic, 2Ozaki Eye Clinic, Miyazaki, Japan; 3Unoki Eye Clinic, Kagoshima, Japan; 4Dake Eye Clinic, Nagasaki, Japan; 5Eto Eye Clinic, Oita, Japan; 6Arai Eye Clinic, Fukuoka, JapanPurpose: We compared the intraocular pressure (IOP)-lowering effect of tafluprost 0.0015% once daily with travoprost 0.004% once daily in Japanese patients with normal-tension glaucoma (NTG).Methods: One hundred sixteen patients with NTG were randomized to use tafluprost 0.0015% or travoprost 0.004% once daily for 12 weeks, followed by a washout period of 4 weeks between switching medications. IOP was measured at baseline and 4, 8, and 12 weeks of each treatment period.Results: Ninety patients completed both treatment periods and had IOP data available for evaluation. In both groups, a significant decrease in IOP was observed for all measurement points compared with baseline values (P &lt; 0.0001). There was no significant difference in IOP at each time point between the two groups. Both drugs were effective (defined as more than 10% IOP reduction) in 39 (43%) of 90 patients; only tafluprost was effective in 26 (29%) patients, and only travoprost was effective in 17 (19%) patients. Eight (9%) patients were nonresponders to both drugs.Conclusions: Tafluprost and travoprost were equally effective in lowering IOP in patients with normal-tension glaucoma. However, patients with normal-tension glaucoma may vary in response to each medication.Keywords: intraocular pressure reduction, normal-tension glaucoma, responder, tafluprost 0.005%, travoprost 0.004%Mizoguchi TOzaki MUnoki KDake YEto TArai MDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1579-1584 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Mizoguchi T Ozaki M Unoki K Dake Y Eto T Arai M A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
description	Takanori Mizoguchi,1 Mineo Ozaki,2 Kazuhiko Unoki,3 Yoshinori Dake,4 Takahiko Eto,5 Miki Arai61Mizoguchi Eye Clinic, 2Ozaki Eye Clinic, Miyazaki, Japan; 3Unoki Eye Clinic, Kagoshima, Japan; 4Dake Eye Clinic, Nagasaki, Japan; 5Eto Eye Clinic, Oita, Japan; 6Arai Eye Clinic, Fukuoka, JapanPurpose: We compared the intraocular pressure (IOP)-lowering effect of tafluprost 0.0015% once daily with travoprost 0.004% once daily in Japanese patients with normal-tension glaucoma (NTG).Methods: One hundred sixteen patients with NTG were randomized to use tafluprost 0.0015% or travoprost 0.004% once daily for 12 weeks, followed by a washout period of 4 weeks between switching medications. IOP was measured at baseline and 4, 8, and 12 weeks of each treatment period.Results: Ninety patients completed both treatment periods and had IOP data available for evaluation. In both groups, a significant decrease in IOP was observed for all measurement points compared with baseline values (P &lt; 0.0001). There was no significant difference in IOP at each time point between the two groups. Both drugs were effective (defined as more than 10% IOP reduction) in 39 (43%) of 90 patients; only tafluprost was effective in 26 (29%) patients, and only travoprost was effective in 17 (19%) patients. Eight (9%) patients were nonresponders to both drugs.Conclusions: Tafluprost and travoprost were equally effective in lowering IOP in patients with normal-tension glaucoma. However, patients with normal-tension glaucoma may vary in response to each medication.Keywords: intraocular pressure reduction, normal-tension glaucoma, responder, tafluprost 0.005%, travoprost 0.004%
format	article
author	Mizoguchi T Ozaki M Unoki K Dake Y Eto T Arai M
author_facet	Mizoguchi T Ozaki M Unoki K Dake Y Eto T Arai M
author_sort	Mizoguchi T
title	A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
title_short	A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
title_full	A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
title_fullStr	A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
title_full_unstemmed	A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
title_sort	randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/7a83617bd98544128a10758012128c47
work_keys_str_mv	AT mizoguchit arandomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT ozakim arandomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT unokik arandomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT dakey arandomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT etot arandomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT araim arandomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT mizoguchit randomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT ozakim randomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT unokik randomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT dakey randomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT etot randomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma AT araim randomizedcrossoverstudycomparingtafluprost0005withtravoprost0004inpatientswithnormaltensionglaucoma
_version_	1718403447568465920

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Ejemplares similares